Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
54
BMRN Quote, Financials, Valuation and Earnings
Last price:
$61.35
Seasonality move
:
5.52%
Day range:
$58.75 - $61.47
52-week range:
$50.76 - $73.51
Dividend yield:
0%
P/E ratio:
22.21x
P/S ratio:
3.76x
P/B ratio:
1.88x
Volume:
5.3M
Avg. volume:
3.3M
1-year change:
-9.72%
Market cap:
$11.4B
Revenue:
$2.8B
EPS (TTM):
$2.67
Analysts' Opinion
-
Consensus RatingBioMarin Pharmaceutical, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $89.43, BioMarin Pharmaceutical, Inc. has an estimated upside of 50.87% from its current price of $59.28.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $60.00 representing -1.22% downside risk from its current price of $59.28.
Fair Value
-
According to the consensus of 20 analysts, BioMarin Pharmaceutical, Inc. has 50.87% upside to fair value with a price target of $89.43 per share.
BMRN vs. S&P 500
-
Over the past 5 trading days, BioMarin Pharmaceutical, Inc. has overperformed the S&P 500 by 11.14% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BioMarin Pharmaceutical, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioMarin Pharmaceutical, Inc. has grown year-over-year revenues for 15 quarters straight. In the most recent quarter BioMarin Pharmaceutical, Inc. reported revenues of $786.8M.
Earnings Growth
-
BioMarin Pharmaceutical, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter BioMarin Pharmaceutical, Inc. reported earnings per share of -$0.16.
Enterprise value:
10.5B
EV / Invested capital:
1.58x
Price / LTM sales:
3.76x
EV / EBIT:
12.30x
EV / Revenue:
3.41x
PEG ratio (5yr expected):
0.37x
EV / Free cash flow:
12.74x
Price / Operating cash flow:
14.04x
Enterprise value / EBITDA:
11.22x
Gross Profit (TTM):
$2.5B
Return On Assets:
7.22%
Net Income Margin (TTM):
16.87%
Return On Equity:
8.99%
Return On Invested Capital:
8.12%
Operating Margin:
23.5%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.3B | $2.7B | $3.1B | $742.4M | $786.8M | |
| Gross Profit | $1.7B | $2.1B | $2.5B | $548.9M | $641.8M | |
| Operating Income | $112.9M | $390.8M | $855.4M | $154.1M | $184.9M | |
| EBITDA | $214.8M | $490.4M | $938.2M | $173.1M | $203.4M | |
| Diluted EPS | $0.76 | $1.66 | $2.67 | $0.55 | -$0.16 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.3B | $2.7B | $3B | $3.1B | $3.9B | |
| Total Assets | $6B | $6.3B | $6.8B | $6.9B | $7.6B | |
| Current Liabilities | $514.9M | $521M | $1.2B | $715.7M | $798.4M | |
| Total Liabilities | $1.7B | $1.7B | $1.9B | $1.4B | $1.6B | |
| Total Equity | $4.3B | $4.6B | $4.9B | $5.4B | $6.1B | |
| Total Debt | $1.1B | $1.1B | $1.1B | $602.7M | $604.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $138.6M | $414.7M | $914M | $221.5M | $368.7M | |
| Cash From Investing | -$101M | -$4.9M | -$295.4M | -$16.2M | -$331M | |
| Cash From Financing | -$18.7M | -$518.5M | -$42.7M | -$499.1M | -$2.2M | |
| Free Cash Flow | $31.3M | $300.9M | $825.8M | $200.3M | $334.9M | |
BMRN
Sector
Market Cap
$11.4B
$28.4M
Price % of 52-Week High
80.64%
51.17%
Dividend Yield
0%
0%
Shareholder Yield
0.79%
-1.49%
1-Year Price Total Return
-9.72%
-16.67%
Beta (5-Year)
0.299
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$54.30
200-day SMA
Buy
Level
$57.88
Bollinger Bands (100)
Buy
Level
52.65 - 57.47
Chaikin Money Flow
Buy
Level
164.8M
20-day SMA
Buy
Level
$54.44
Relative Strength Index (RSI14)
Buy
Level
65.44
ADX Line
Buy
Level
20.76
Williams %R
Neutral
Level
-35.4888
50-day SMA
Buy
Level
$53.75
MACD (12, 26)
Buy
Level
0.58
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Neutral
Level
262.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.7207)
Buy
CA Score
(Annual)
Level (1.2674)
Buy
Beneish M-Score
(Annual)
Level (-2.4169)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-3.8585)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Stock Forecast FAQ
In the current month, BMRN has received 13 Buy ratings 7 Hold ratings, and 0 Sell ratings. The BMRN average analyst price target in the past 3 months is $89.43.
-
Where Will BioMarin Pharmaceutical, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioMarin Pharmaceutical, Inc. share price will rise to $89.43 per share over the next 12 months.
-
What Do Analysts Say About BioMarin Pharmaceutical, Inc.?
Analysts are divided on their view about BioMarin Pharmaceutical, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioMarin Pharmaceutical, Inc. is a Sell and believe this share price will drop from its current level to $60.00.
-
What Is BioMarin Pharmaceutical, Inc.'s Price Target?
The price target for BioMarin Pharmaceutical, Inc. over the next 1-year time period is forecast to be $89.43 according to 20 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is BMRN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioMarin Pharmaceutical, Inc. is a Buy. 13 of 20 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BMRN?
You can purchase shares of BioMarin Pharmaceutical, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioMarin Pharmaceutical, Inc. shares.
-
What Is The BioMarin Pharmaceutical, Inc. Share Price Today?
BioMarin Pharmaceutical, Inc. was last trading at $61.35 per share. This represents the most recent stock quote for BioMarin Pharmaceutical, Inc.. Yesterday, BioMarin Pharmaceutical, Inc. closed at $59.28 per share.
-
How To Buy BioMarin Pharmaceutical, Inc. Stock Online?
In order to purchase BioMarin Pharmaceutical, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BMRN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BMRN
Sector
P/E ratio
22.21x
23.89x
PEG ratio
0.37x
-0.01x
P/B ratio
1.88x
1.81x
Price / LTM sales
3.76x
1.58x
Growth Metrics
BMRN
Sector
Revenue growth
5.98%
4.62%
Earnings growth
-129.25%
10.7%
Revenue (5-year growth)
10.98%
6.5%
Earnings forecast
$0.34
-$0.21
Profitability
BMRN
Sector
Profitability FY 2024
$2.2B
$3.6M
Return on invested capital
8.12%
-31.84%
Return on assets
7.22%
-27.96%
Return on equity
8.99%
-37.63%
Earnings Date
Last Earnings Date
Oct
27
Next Earnings Date
Feb
19
Estimated Next Earnings Date
Jan
26
Balance Sheet
BMRN
Sector
Total cash
$1.5B
$26.4M
Short term investments
$194.9M
$25.7M
Total assets
$7B
$76.9M
Long term debt
$604.2M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 4.51% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is up 0.04% over the past day.
Buy
60
ZBIO alert for Dec 23
Zenas BioPharma, Inc. [ZBIO] is down 0.54% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
